Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Effectiveness of FDG PET-CT Versus Contrast-Enhanced CT in Oesophagogastric Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy

  • By

  • J. L. Moore

  • M. Arora

  • C. Sit

  • R. Rahman

  • M. Green

  • H. Deere

  • J. Lagergren

  • S. Chicklore

  • F. Chinaka

  • N. Maisey

  • S. Ngan

  • A. Sita-Lumsden

  • A. Qureshi

  • K. Owczarczyk

  • W. R. C. Knight

  • M. Kelly

  • C. R. Baker

  • J. A. Gossage

  • M. Subesinghe

  • A. R. Davies

  • September 17, 2026

Share

Objective:

To compare post-NACT CECT with FDG PET-CT for accuracy in predicting tumor invasion depth (ypT stage), pathological nodal disease (ypN stage), and distant metastatic disease among patients with oesophagogastric adenocarcinoma.

Approach:
  • Imaging Protocols: FDG PET-CT and CECT were performed using GE Discovery 710 systems, with protocols for fasting of at least 6 hours before imaging, administration of 350 MBq ± 10% FDG, and specific imaging parameters for both modalities.
Key Findings:
  • FDG PET-CT is increasingly utilized for assessing treatment response, while CECT remains the most commonly used imaging technique.
  • Decreased FDG avidity post-NACT is correlated with improved pathological response and survival.
  • There is no consensus on the optimal imaging modality for predicting pathological stage and treatment response.
Interpretation:

The study discusses the ongoing debate regarding the effectiveness of imaging modalities for assessing treatment response in oesophagogastric adenocarcinoma patients post-NACT.

Limitations:
  • The study was conducted at a single institution, which may limit generalizability.
  • The retrospective nature of the study may introduce selection bias.
Conclusion:

Further research is required to establish the comparative effectiveness of FDG PET-CT versus CECT in predicting outcomes in this patient population.

Original Source(s)

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy

  • by J. L. Moore, M. Arora, C. Sit, R. Rahman, M. Green, H. Deere, J. Lagergren, S. Chicklore, F. Chinaka, N. Maisey, S. Ngan, A. Sita-Lumsden, A. Qureshi, K. Owczarczyk, W. R. C. Knight, M. Kelly, C. R. Baker, J. A. Gossage, M. Subesinghe, A. R. Davies

  • September 17, 2026

Related Content

Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα

Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027

U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.

  • by

  • September 15, 2026

  • 3 min
Predictors of Delayed and Omitted Postoperative Radiotherapy After Laryngectomy for pT4 Laryngeal Cancer